Financings in Brief: Urohealth Systems
This article was originally published in The Gray Sheet
Executive SummaryUrohealth Systems: Costa Mesa, California-based manufacturer of the Cen-slide system for microscopic urine analysis and the Dristar product for incontinence, completes its stock acquisition of Dacomed Corporation. The deal gives Urohealth, formerly called Davstar Industries, several additional urological products, including the Dura II penile implant, the Rigiscan diagnostic product for rigidity, and the Catalyst vacuum device. Under the deal, Dacomed shareholders were issued 5.2 mil. shares of Urohealth stock. The merger, valued at about $19 mil., is Urohealth's second recent acquisition in the urology area. In another deal that closed near the end of July, the company issued 571,000 shares to acquire Allstate Medical, an incontinence products manufacturer. In separate news, Urohealth says it has issued to FoxMeyer Health Corporation $2.5 mil. in exchangeable convertible preferred stock, and warrants to purchase 2.4 mil. common shares, as FoxMeyer fulfills its commitment to invest $5 mil. in the company...
You may also be interested in...
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.